Unibest

Pharmaceutical intermediates

Letermovir Intermediates

4 pharmaceutical intermediates for Letermovir. Indication: Cytomegalovirus Infection.

提交项目All intermediates

About Letermovir

Originator
Aicuris
Indication
Cytomegalovirus Infection
Approved Date
11/08/2017
DS/DP
06/05/2026

Available intermediates

4 intermediates currently listed for Letermovir. Request specifications, documentation or a quotation for any item below.

Letermovir intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
2-Propenoic acid, 3-[3-fluoro-2-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenyl]-, methyl ester, (2E)-917389-26-5//
2-Propenoic acid, 3-[3-fluoro-2-[(phenoxycarbonyl)amino]phenyl]-, methyl ester, (2E)-1791412-01-5//
2-(8-fluoro-3-(2-methoxy-5-(trifluoromethyl)phenyl) -2-oxo-1,2,3,4-tetrahydroquinazolin-4-yl) acetic acid methyl ester917389-21-0//
1-(3-Methoxyphenyl)Piperazine Hydrochloride16015-70-6//

Other programs under L

(LCZ696)LanifibranorLapatinibLarotrectinibLasmiditanLazertinib MesylateLemborexantLenacapavir sodium

Building toward Letermovir?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →